Thermal and long period stability of series of V(V), V(IV) and V(III) complex with Schiff base ligands in solid state

• Autorzy: Szklarzewicz Janusz , Jurowska Anna , Hodorowicz Maciej , Gryboś Ryszard

Identyfikatory

DOI

10.5604/01.3001.0013.1547

• Języki publikacji: EN

Abstrakty

EN

The synthesis and physicochemical properties of three new complexes of vanadium at +5, +4 and +3 oxidation state are described and discussed. The octahedral surrounding of vanadium for V(III) complexes of [V(L¹)(HL¹)] general formula is filled with two ONO tridentate ligand L, for V(IV) one ONO ligand L, oxido ligand and 1,10-phenanthroline (phen) as a co-ligand are presented in complexes of [VO(L²)(phen)]. For V(V) the complexes of [VO²(L¹)(solv)] type were formed. As ligands, the H²L Schiff bases were formed in reaction between 5-hydroxysalcylaldehyde and phenylacetic hydrazide (H²L¹) and 3,5- dichlorosalicyaldehyde and 4-hydroxybenzhydrazide (L²). The magnetic moment measurements, in 8 year period, show, that V(III) complexes slowly oxidise to V(IV) with preservation of the nonoxido character of the complexes, while V(IV) complexes were found to be stable. The TG and SDTA measurements indicate, that thermal stability depends mainly on the oxidation state of vanadium. The less thermally stable are the V(V) complexes, while V(IV) and V(III) are stable up to ca. 200^oC. In solution, at pH 2 (similar to that in human digestion system), again the V(IV) are the most stable, only at pH 7.0 V(III) complexes had higher stability. The most stable, thus best for pharmaceutical use, are V(IV) complexes.

Słowa kluczowe

EN

vanadium; complex; Schiff base; salicylaldehyde; hydrazide; thermogravimetry

PL

wanad; kompleks; baza Schiffa; aldehyd salicylowy; hydrazyd; termograwimetria

• Wydawca: Państwowa Wyższa Szkoła Zawodowa w Tarnowie
• Czasopismo: Science, Technology and Innovation
• Rocznik: 2019
• Tom: Vol. 4, no. 1
• Strony: 30--36
• Opis fizyczny: Bibliogr. 18 poz., rys., tab.

Twórcy

autor

Szklarzewicz Janusz

• Jagiellonian University, Faculty of Chemistry, 30-387 Kraków, Gronostajowa 2, Poland

autor

Jurowska Anna

• Jagiellonian University, Faculty of Chemistry, 30-387 Kraków, Gronostajowa 2, Poland

autor

Hodorowicz Maciej

• Jagiellonian University, Faculty of Chemistry, 30-387 Kraków, Gronostajowa 2, Poland

autor

Gryboś Ryszard

• Jagiellonian University, Faculty of Chemistry, 30-387 Kraków, Gronostajowa 2, Poland

Bibliografia

• 1. Brannick B, Kocak Solomon S. Vanadium in Glucose Metabolism: Past, Present and Future. Journal of Toxicology and Pharmacology. 2017; 1:1-011.
• 2. Lyonnet B, Martz, Martin E. L’emploi du vanadium. La Presse Medicale. 1989; 1:191-192.
• 3. Hamel FG, Solomon SS, Jespersen AS, Blotcky A, Rack E, Duckworth WC. Alteration of tissue vanadium content in diabetes. Metabolism. 1993; 42:1503–1505.
• 4. Smith DM, Pickering RM, Lewith GT. A systematic review of vanadium oral supplements for glycaemic control in type 2 diabetes mellitus. Q.J.Med. 2008; 101:351-358.
• 5. Wang J, Yuen VG, McNeill JH, Effects of vanadium on insulin sensitivity and appetite. Metabolism. 2001; 50:667-673.
• 6. Barceloux DG. Vanadium. Journal of Toxicology: Clinical Toxicology. 1999; 37:265-278.
• 7. Domingo JL, Gomez M. Vanadium compounds for the treatment of human diabetes mellitus: A scientific curiosity? A review of thirty years of research. Food and Chemical Toxicology. 2016; 95:137-141.
• 8. Thompson KH, Orvig Ch, Vanadium in diabetes: 100 years from Phase 0 to Phase I. Journal of Inorganic Biochemistry. 2006; 100:1925-1935.
• 9. Cusi K, Cukier S, DeFronzo RA, Torres M, Puchulu FM, Redondo JC. Vanadyl Sulfate Improves Hepatic and Muscle Insulin Sensitivity in Type 2 Diabetes. The Journal of Clinical Endocrinology and Metabolism. 2001; 86:1410–1417.
• 10. Thompson KH, Lichter J, Lebel C, Scaife MC, McNeill JH, Orvig Ch. Vanadium treatment of type 2 diabetes: A view to the future. Journal of Inorganic Biochemistry. 2009; 103:554-558.
• 11. Jakusch, T, Kiss, T. In vitro study of the antidiabetic behavior of vanadium compounds. Coordination Chemistry Reviews. 2017; 351: p. 118-126.
• 12. McNeill JH, Yuen VG, Hoveyda HR, Orvig C. Bis(maltolato)oxovanadium(IV) is a potent insulin mimic. Journal of Medicinal Chemistry. 1992; 35:1489–1491.
• 13. Peters KG, Davis MG, Howard BW, Pokross M, Rastogi V, Diven C, Greis KD, Eby-Wilkens E, Maier M, Evdokimov A, Soper S, Genbauffe F. Mechanism of insulin sensitization by BMOV (bis maltolato oxo vanadium); unliganded vanadium (VO4) as the active component. Journal of Inorganic Biochemistry. 2003; 96:321-330.
• 14. Ki J, Mukherjee A, Rangasamy S, Purushothaman B, Song JM. Insulin-mimetic and anti-inflammatory potential of a vanadyl-Schiff base complex for its application against diabetes. RSC Advances. 2016;6:57530-57539.
• 15. Lofti N, Sheikhshoaei I, Ebrahimipour SY, Krautscheid H. Synthesis, characterization, crystal structure and DFT studies of a cis dioxo-vanadium(V) complex containing a tridentate (NNO) Schiff base ligand. Journal of Molecular Structure. 2017; 1149:432-438.
• 16. Gryboś R, Szklarzewicz J, Jurowska A, Hodorowicz M. Properties, structure and stability of V(IV) hydrazide Schiff base ligand complex. Journal of Molecular Structure. 2018;1171:880-887.
• 17. Szklarzewicz, J, Jurowska, A, Olszewska, A, Hodorowicz, M, Synthesis, structure and properties of V(III,IV and V) complexes with ONO Schiff bases. Science, Technology and Innovation. This issue.
• 18. Jurowska A, Szklarzewicz J, Hodorowicz M, Gryboś R. Synthesis, structure and properties of V(V) monooxido complex with ONO tridentate Schiff base. Science, Technology and Innovation. This issue

Uwagi

Opracowanie rekordu w ramach umowy 509/P-DUN/2018 ze środków MNiSW przeznaczonych na działalność upowszechniającą naukę (2019).